Synapse - Saad Usmani

Results (296)

Daratumumab (DARA) in combination with bortezomib plus dexamethasone (D-Vd) or lenalidomide plus dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of the phase 3 CASTOR and POLLUX studies in patients (pts) with early or late relapse after initial therapy

Meeting Abstract

Spencer, A.; Moreau, P.; Mateos, M. V.; Goldschmidt, H.; Suzuki, K.; Levin, M. D.; Sonneveld, P.; Yoon, S. S.; Usmani, S. Z.; Weisel, K.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Impact of second primary malignancy post-autologous hematopoietic stem cell transplantation on outcomes of multiple myeloma: A CIBMTR analysis

Meeting Abstract

Ragon, B. K.; D'Souza, A.; Estrada-Merly, N.; Fraser, R.; George, G.; Gowda, L.; Shah, N.; Qazilbash, M. H.; Kumar, S.; Horowitz, M. M.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Outcomes for transplant-eligible, newly diagnosed Black patients (Pts) with multiple myeloma (MM): The Levine Cancer Institute (LCI) experience

Meeting Abstract

Paul, B.; Atrash, S.; Robinson, M. M.; Jagosky, M.; Bhutani, M.; Varga, C.; Pineda-Roman, M.; Friend, R. N.; Foureau, D.; Cassetta, K.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Matching-adjusted indirect treatment comparison (MAIC) of teclistamab (tec) versus belantamab mafodotin (belamaf) for the treatment of patients (pts) with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM)

Meeting Abstract

Moreau, P.; Usmani, S. Z.; van de Donk, N. W. C. J.; Garfall, A. L.; Delforge, M.; Rocafiguera, A. O.; Nooka, A. K.; Rosiñol, L.; Bahlis, N. J.; Rodríguez-Otero, P.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Indirect treatment (tx) comparison of teclistamab (tec) in MajesTEC-1 versus physician's choice of therapy in the long-term follow-up of the CASTOR, POLLUX, EQUULEUS, and APOLLO trials in patients (pts) with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM)

Meeting Abstract

Mateos, M. V.; Chari, A.; Usmani, S. Z.; Goldschmidt, H.; Weisel, K.; Qi, K. Q.; Londhe, A.; Nair, S.; Lin, X. W.; Pei, L. X.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Comparative effectiveness of teclistamab versus real-world treatments for patients with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM)

Meeting Abstract

Krishnan, A. Y.; Nooka, A. K.; Chari, A.; Garfall, A. L.; Martin, T. G.; Nair, S.; Lin, X. W.; Qi, K. Q.; Londhe, A.; Pei, L. X.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Time to response, duration of response, and patient-reported outcomes (PROs) with daratumumab (DARA) plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): Subgroup analysis of the phase 3 MAIA study

Meeting Abstract

Facon, T.; Kumar, S.; Plesner, T.; Moreau, P.; Bahlis, N. J.; Goldschmidt, H.; O'Dwyer, M.; Perrot, A.; Christopher; Venner, P.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Clinical efficacy of daratumumab (DARA)-based second line therapy after DARAcontaining and DARA-free induction therapies in multiple myeloma: A single center experience

Meeting Abstract

Ciardiello, A.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Lu, S. X.; Patel, D.; Maclachlan, K.; Lahoud, O. B.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Matching-adjusted indirect comparison (MAIC) of teclistamab (tec) versus selinexordexamethasone (sel-dex) for the treatment of patients (pts) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)